Care needed in interpretation of cancer survival measures  by Rutherford, Mark J
Comment
1162 www.thelancet.com   Vol 385   March 28, 2015
Care needed in interpretation of cancer survival measures
Cancer patient survival obtained from population-based 
cancer studies is the optimum method to monitor and 
assess the eﬀ ectiveness of patient care.1 Consideration 
of these estimates in conjunction with estimates of 
cancer incidence and mortality is still important.2 As 
a result, there is much interest in the assessment of 
progress in terms of cancer survival.3,4 Quantiﬁ cation of 
the improvements in cancer patient survival because of 
successes in some areas, such as treatment, diagnostic 
techniques, and awareness or screening campaigns, 
is of paramount importance to health-care oﬃ  cials, 
health policy makers, and charities supporting these 
developments in cancer control. However, to make a fair 
comparison—to compare like with like—is essential to 
assess progress accurately.
In The Lancet, Manuela Quaresma and colleagues5 
report the creation of a survival index that is useful 
to compare improvements in cancer patient survival 
over time. The authors show that the index of net 
survival increased substantially in cancer patients in 
England and Wales over the period 1971–2011. To make 
comparisons across time for all cancer sites combined 
is diﬃ  cult because of changing age distributions for 
patients with cancer alongside a changing distribution 
of sites. For instance, if less fatal cancers become 
relatively more common, an improvement would be 
seen in all-cancer survival, but not necessarily because 
of any improvements for any individual cancer site. 
One further issue with comparisons of survival after 
cancer is that the chance of dying from another cause 
also changes over time. Quaresma and colleagues5 
overcome these diﬃ  culties by deﬁ ning a survival index 
that estimates average relative survival in diﬀ erent 
time periods, but the index is standardised to the 
distribution of both age and cancer site in 1996–99. 
Relative survival compares the survival in patients 
with cancer to a relevant cohort without cancer, and is 
important to account for the changing risk of dying of 
something else. Under speciﬁ c assumptions,6 average 
relative survival estimates marginal net survival, which 
is completely independent of other-cause mortality. The 
standardisation to 1996–99 neatly overcomes the other 
issues of comparability (age and cancer distributions), 
but comes at the cost of the inability to interpret the 
measures. Measures that are optimum for comparability 
cannot be easily interpreted in terms of the survival 
experience of individuals, and vice versa.
The authors note that the ﬁ gures they report are 
readily interpreted incorrectly.7,8 The survival index 
for all cancers combined is something of a holy grail 
for headline writers, because it gives one summary 
ﬁ gure to show progress in cancer as a whole over time. 
However, similarly to all averages and summaries, 
important detail lies behind the number. The survival 
index (and the site-speciﬁ c estimates) measure net 
survival, which adds substantially to the diﬃ  culty in 
interpretation, but that subtlety is often missed. The 
all-cancer survival index of 50% at 10 years might be 
interpreted as meaning that 50% of cancer patients 
will survive for 10 years or more, which is wrong—
as the authors discuss5—but it is worth stressing 
this point. The problem relates to the three main 
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10-year net 
probability of death 
(1–relative survival)
10-year crude (actual) 
probability of death 
due to cancer
10-year crude (actual) 
probability of death 
due to other causes
10-year crude (actual) 
probability of death 
due to any cause
40 years 0·50 0·49 0·02 0·51
60 years 0·50 0·48 0·08 0·57
80 years 0·50 0·42 0·42 0·84
Derived from an England and Wales life table. Columns 2 and 3 give the actual probabilities of death due to the disease 
and due to other causes, and sum to the value given in column 4 (the overall probability of death). The ﬁ rst column 
gives a net measure and has no interpretation as the actual probability of death due to cancer.
Table: Synthetic example of survival by patient age in which 10-year net survival is 50% for all ages
Comment
www.thelancet.com   Vol 385   March 28, 2015 1163
adjustments necessary for making the index possible 
to compare across time. The measure is independent of 
competing mortality because of other causes that also 
heavily aﬀ ect patients with cancer; for most sites, the 
diagnosed patients are of an older age.
I show an example in which the relative survival 
estimate at 10 years is 50% at every age. England and 
Wales population mortality data are used to convert 
these estimates9,10 into the 10 year all-cause probability 
of death (table). An 80-year-old has a 16% chance of 
being alive at 10 years, despite the net estimate of 50%. 
For younger patients, the diﬀ erences are smaller, but 
still exist. Overall, fewer patients with cancer will be 
alive 10 years after diagnosis if we use all-cause death as 
the outcome, rather than a net measure. Diﬃ  culties are 
also introduced by standardisation; patients with cancer 
diagnosed now (and in the future) might be older on 
average, and have a higher proportion of cancers with a 
better or worse prognosis than in 1996–99. The survival 
index is being standardised to a population that might 
not be a good representation of the present population 
structure, making present and future interpretability 
of the measure more diﬃ  cult. Additionally, any biases 
in site-speciﬁ c estimates will also contribute to the 
survival index.
Quaresma and colleagues mainly concentrate on 
age-standardised measures. However, the age-group 
speciﬁ c estimates need to be examined across each 
site to understand fully whether improvements in 
outcomes occur across all ages simultaneously, which is 
unlikely to be the case. For instance, certain treatment 
improvements will be seen only for younger patients. 
Although the overall measures reported as headline 
ﬁ gures are important, understanding of the reasons 
for the changes over time is even more important. 
Quaresma and colleagues ﬁ t very sophisticated models 
to arrive at the values that they present. A lot of extra 
information can be garnered from these models. Metrics 
that underline in which subgroups of patients and at 
what point in follow-up improvements have occurred 
should be further used.11,12
Overall, Quaresma and colleagues should be 
congratulated on a carefully constructed method 
for comparisons across time. This is a useful 
epidemiological measure for quantiﬁ cation of overall 
improvements in cancer survival. The site-speciﬁ c 
indices are particularly useful to understand whether 
progress has been made and when in calendar time we 
observe the improvement. However, caution should be 
used when interpreting the ﬁ gures themselves. I would 
encourage the continued development of statistical 
approaches that help to pinpoint the reasons for these 
overall improvements. I would also further stress 
that other statistical metrics, which are more readily 
interpretable for patients and health-care professionals, 
should be used.12
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